-+ 0.00%
-+ 0.00%
-+ 0.00%

Changchun Hi-Tech (000661.SZ) subsidiary GenSci 133 injection drug registration application for domestically produced drugs was accepted

Zhitongcaijing·08/05/2026 09:17:04
Listen to the news

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), the holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the registration clinical trial application for domestically produced drugs of Jinsai Pharmaceutical GenSci133 injection was accepted. This drug is a PTH polypeptide and anti-RANKL antibody fusion protein independently developed by Jinsai Pharmaceutical. It belongs to class 1 of therapeutic biological products and is intended to treat osteoporosis.